Back to Search Results


Metabolic Syndrome

Author: Anitra D. Beasley, MD

Mentor: Laurie Swaim, MD
Editor: Julie A Zemaitis DeCesare, MD

Registered users can also download a PDF or listen to a podcast of this Pearl.
Log in now, or create a free account to access bonus Pearls features.

The metabolic syndrome encompasses a cluster of risk factors including central obesity, dyslipidemia, elevated blood pressure, and raised fasting glucose. Together these factors increase the risk of atherosclerotic cardiovascular disease, type 2 diabetes, and all-cause mortality. Development of metabolic syndrome is associated with elevated body mass index (BMI), sedentary lifestyle, low socioeconomic status and advancing age. Due to the increasing prevalence of obesity in the United States, metabolic syndrome is a common problem. As of 2016, approximately 36% of adult women in the United States met criteria for the syndrome.

There are several definitions for the metabolic syndrome, with the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) the most commonly used. Based on the NCEP ATP III criteria, clinical diagnosis in women relies on the fulfillment of at least three of the following criteria:

  • HDL cholesterol < 50 mg/dL or drug therapy for low HDL cholesterol
  • Waist circumference > 88 cm (35 in)
  • Systolic blood pressure ≥ 130 mmHg, diastolic blood pressure ≥ 85, or drug therapy for hypertension
  • Fasting plasma glucose ≥ 100 mg/dL or drug therapy for hyperglycemia
  • Triglyceride level > 150 mg/dL or drug therapy for elevated triglycerides

More recent revisions to the definition validate these criteria but also call for ethnic, regional, and country specific values for elevated waist measurement.

The most accepted theory to describe the underlying cause of the metabolic syndrome is insulin resistance. Metabolic syndrome is a predictor for cardiovascular disease and type 2 diabetes. Once disease develops, the individual components promote disease progression. There are typically no associated symptoms; however nonalcoholic fatty liver disease, hyperuricemia, polycystic ovarian syndrome, and obstructive sleep apnea may coexist due to shared risk factors.

Weight reduction, increased physical activity, and behavior modification are the mainstays of therapy. A weight loss of 5-10% over 6 to 12 months through reduced caloric intake and moderate intensity exercise on most days of the week is recommended. Diets with an emphasis on fruits, vegetables, fish, and whole grains and restricted in saturated and trans-fats are recommended. Exercise may have additional benefits beyond its effect on weight loss by selectively removing abdominal fat. In some patients, treatment beyond lifestyle modification is required and may include weight-loss medications or bariatric surgery. Typically, surgery is an option for patients who have a BMI > 40 kg/m2 or BMI > 35 kg/m2 with comorbidities. Cardiovascular risk factors and diabetes should be treated with pharmacologic therapy if they persist despite weight loss and lifestyle modification.


Further Reading:


American Heart Association; National Heart, Lung, and Blood Institute, Grundy SM, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiol Rev. 2005 Nov-Dec;13(6):322-7. PMID: 16708441

American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Gynecology. ACOG Practice Bulletin No. 194: Polycystic Ovary Syndrome. Obstet Gynecol. 2018 Jun;131(6):e157-e171. doi: 10.1097/AOG.0000000000002656. Erratum in: Obstet Gynecol. 2020 Sep;136(3):638. PMID: 29794677.

Initial approval: January 2014; Revised September 2018; Reaffirmed March 2020; Revised November 2021. References revised September 2023


********** Notice Regarding Use ************

The Society for Academic Specialists in General Obstetrics and Gynecology, Inc. (“SASGOG”) is committed to accuracy and will review and validate all Pearls on an ongoing basis to reflect current practice.

This document is designed to aid practitioners in providing appropriate obstetric and gynecologic care. Recommendations are derived from major society guidelines and high-quality evidence when available, supplemented by the opinion of the author and editorial board when necessary. It should not be construed as dictating an exclusive course of treatment or procedure to be followed.

Variations in practice may be warranted when, in the reasonable judgment of the treating clinician, such course of action is indicated by the condition of the patient, limitations of available resources, or advances in knowledge or technology. SASGOG reviews the articles regularly; however, its publications may not reflect the most recent evidence. While we make every effort to present accurate and reliable information, this publication is provided “as is” without any warranty of accuracy, reliability, or otherwise, either express or implied. SASGOG does not guarantee, warrant, or endorse the products or services of any firm, organization, or person. Neither SASGOG nor its respective officers, directors, members, employees, or agents will be liable for any loss, damage, or claim with respect to any liabilities, including direct, special, indirect, or consequential damages, incurred in connection with this publication or reliance on the information presented.

Copyright 2023 The Society for Academic Specialists in General Obstetrics and Gynecology, Inc. All rights reserved.  No re-print, duplication or posting allowed without prior written consent.


Back to Search Results